Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Eur J Radiol ; 61(3): 499-506, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17166681

RESUMO

Hereditary Hemochromatosis is the most frequent modality of iron overload. Since 1996 genetic tests have facilitated significantly the non-invasive diagnosis of the disease. There are however many cases of negative genetic tests that require confirmation by hepatic iron quantification which is traditionally performed by hepatic biopsy. There are many studies that have demonstrated the possibility of performing hepatic iron quantification with Magnetic Resonance. However, a consensus has not been reached yet regarding the technique or the possibility to reproduce the same method of calculus in different machines. This article reviews the state of the art of the question and delineates possible future lines to standardise this non-invasive method of hepatic iron quantification.


Assuntos
Hemocromatose/diagnóstico , Ferro/metabolismo , Fígado/metabolismo , Imageamento por Ressonância Magnética , Hemocromatose/genética , Hemocromatose/metabolismo , Humanos
2.
J Intensive Care Med ; 21(1): 27-39, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16698742

RESUMO

The objective was to evaluate the efficacy and safety of recombinant activated factor VII in patients with massive bleeding. Forty-five patients with severe massive hemorrhage requiring>or= 14 transfusion units of packed red blood cells received recombinant activated factor VII. Postdrug blood loss and transfusion requirements were assessed, and mortality was compared with predicted outcomes. Blood loss was markedly reduced in 40 of 43 (93.0%) patients, and transfusion requirements decreased after recombinant activated factor VII administration. Mortality rate in trauma patients who had massive hemorrhage was significantly reduced compared with predictions using scoring systems. This may be associated with the use of recombinant activated factor VII. This study failed to demonstrate an improvement in surgical patients. The absence of concurrent controls prevents definitive conclusions regarding actual safety or efficacy of recombinant activated factor VII.


Assuntos
Perda Sanguínea Cirúrgica/prevenção & controle , Fator VIIa/uso terapêutico , Hemorragia/tratamento farmacológico , Hemorragia/etiologia , Ferimentos e Lesões/complicações , Adolescente , Adulto , Idoso , Canadá , Relação Dose-Resposta a Droga , Europa (Continente) , Feminino , Técnicas Hemostáticas , Humanos , Escala de Gravidade do Ferimento , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Medição de Risco/métodos , Análise de Sobrevida , Resultado do Tratamento , Ferimentos e Lesões/classificação
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa